Don't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag

Regencell Bioscience (NASDAQ: RGC) is an early-stage bioscience company. That alone should be enough to keep most investors on the sidelines, given the risks involved if the medicines the company is working on fail to produce positive results. However, there's another small wrinkle here. Regencells Bioscience is working on something it calls TCM. What is TCM? A high-risk, high-return sector Early-stage healthcare companies are fraught with risk. In essence, they are companies that believe something could ...